No Data
A Quick Look at Today's Ratings for Cytokinetics(CYTK.US), With a Forecast Between $62 to $120
Cytokinetics Opens Enrollment for COMET-HF Phase 3 Trial
Express News | Cytokinetics Announces Start of Comet-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Symptomatic Heart Failure With Severely Reduced Ejection Fraction
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), PTC Therapeutics (PTCT) and Vir Biotechnology (VIR)
Insider Sale: President & CEO of $CYTK (CYTK) Sells 5,000 Shares
Cytokinetics to Participate in December Investor Conferences